

Nuclear Power Plant
P.O. Box 215
Buchanan, New York 10511
914 736.8001



Robert J. Barrett
Plant Manager

September 18, 1996
IPN-96-104

U.S. Nuclear Regulatory Commission
ATTN: Document Control Desk
Washington, D.C. 20555

SUBJECT: Indian Point 3 Nuclear Power Plant
Docket No. 50-286
License No. DPR-64
Unsatisfactory Laboratory Result of a Blind Performance Test

Dear Sir:

This letter provides a report as required by 10 CFR 26, Appendix A, Section 2.8(e)(4). A positive blind performance test was declared negative by the testing lab on August 27, 1996. Attachment I documents the result of an investigation, including corrective action, completed by William E. Wingert, PhD, of LabCorp, as well as the review and approval of the investigation and corrective actions by Peter C. Gay, M.D., for the New York Power Authority.

The Authority is making no new commitments in this letter. If you have any questions contact Mr. D. Plumer at (914) 736-8195.

Very truly yours,

A handwritten signature in cursive script, appearing to read 'Robert J. Barrett'.

Robert J. Barrett
Plant Manager
Indian Point 3 Nuclear Power Plant

Attachment

cc: See next page

A0221/

9609240348 960918
PDR ADOCK 05000286
R PDR

240008

cc: Mr. Hubert J. Miller
Regional Administrator
Region I
U.S. Nuclear Regulatory Commission
475 Allendale Road
King of Prussia, Pennsylvania 19406-1415

Mr. Curtis J. Cowgill III, Chief
Projects Branch No. 1
Division of Reactor Projects
U.S. Nuclear Regulatory Commission
475 Allendale Road
King of Prussia, Pennsylvania 19406-1415

U.S. Nuclear Regulatory Commission
Resident Inspectors' Office
Indian Point 3 Nuclear Power Plant



Docket No. 50-286

IPN-96-104

Attachment I

Page 1 of 4

Laboratory Corporation of America™ Holdings
69 First Avenue
Raritan, New Jersey 08869

Telephone: 800-631-5250
908-526-2400

September 9, 1996

Dale Plumer
Fitness For Duty Program Administrator
Indian Point Three
New York Power Authority
Broadway and Bleakley Avenue
Buchanan, NY 10511

Dear Mr. Plumer:

This is in response to inquiries from you and Carol Soucy concerning reports generated on specimen numbers 234-527-5020-0 and 238-527-5010-0. As stated in my previous letter (attachment 1), drug profile 730457 is somewhat complicated to data enter because of the additional steps we have been taking to enter results as NEGATIVE or POSITIVE, rather than the usual numerical values. After conferring with Dr. Wolf and Dr. Gay, we all have agreed that we must continue to enter results as NEGATIVE or POSITIVE to be in compliance with the NRC regulations. After thoroughly investigating alternatives, I have implemented a standardized, more concise method for data entry which all Certifying Scientists will be required to follow. A memorandum outlining this policy is attached (attachment 2).

It is our intent to provide the NRC and all our clients with the best service possible. We appreciate the opportunity to address these concerns so that this is accomplished. If you have any questions or comments, please do not hesitate to contact me at (800) 437-4986.

Sincerely,

William E. Wingert, PhD
Laboratory Director,
Forensic Toxicology



Docket No. 50-286
IPN-96-104
Attachment I
Page 2 of 4

Laboratory Corporation of America™ Holdings
69 First Avenue
Raritan, New Jersey 08869

Telephone: 800-631-5250
908-526-2400

September 4, 1996

Dale Palmer
Fitness For Duty Program Administrator
Indian Point Three
New York Power Authority
Broadway and Bleakley Avenue
Buchanan, NY 10511

Dear Mr. Palmer:

This is in response to your previous inquiry regarding the report generated on specimen number 234-527-5020 (employee #234-55-7169). As you are aware, the original report (Attachment #1) indicated a negative Opiate and a negative 6-monoacetylmorphine. Since 6-monoacetylmorphine definitely would not be run if either the Opiate initial screen or the morphine GC/MS confirmation were negative, the only way this report could have been generated was if the morphine bucket was incorrectly completed during the data entry process.

Up to this time, we have reported numerous drug screen panels to the NRC and have not experienced a problem. However, the NRC drug profile 730457 is somewhat complicated to data enter since we have been taking additional steps to enter results as NEGATIVE or POSITIVE rather than the usual numerical values. Unless there are objections from the NRC, the problem should be remedied by reporting the drug screens (excluding 6-MAM) as numerical results. Please let me know if this change is acceptable.

Also enclosed are copies of the amended report (Attachment #2) and Copy 1 of the certified report (Attachment #3). We sincerely apologize for any inconvenience that may have resulted.

Sincerely,

William E. Wingert, PhD
Laboratory Director,
Forensic Toxicology



Docket No. 50-286

IPN-96-104

Attachment I

Page 3 of 4

Laboratory Corporation of America™ Holdings
69 First Avenue
Raritan, New Jersey 08869

Telephone: 800-631-5250
908-526-2400

TO: All Certifying Scientists

FROM: Bill Wingert, PhD

W 9/6/96

DATE: September 6, 1996

RE: Standardized method for data entry of GC/MS confirmation results for
Nuclear Regulatory Commission (NRC) specimens

1. Recently, several reports have been received by the NRC which contained errors made in the data entry of GC/MS confirmation results (NRC specimens are numbered in 527-5000 series).
2. We previously had agreed to enter these results as "NEG" or "POS" in the test bucket changing the 0 designation to L (literal).
3. To simplify and standardize the data entry process, all GC/MS results now should be entered in the test bucket on the 10 screen using an "N" or "P" and changing the "0" designation in the test (T) column to "A" (abbreviation).
4. Please initial and date this memo to indicate that you understand and will comply with it.

**MEDICUS, P.C.**

Docket No. 50-286

IPN-96-104

Attachment I

Page 4 of 4

MID-HUDSON IMMEDIATE MEDICAL SERVICES

September 12, 1996

Dale Plumer, R.N.
New York Power Authority
P.O. 215
Buchanan, NY 10511

Re: Letter To Mr. Plumer and Memo to All Certifying Scientists
From Bill Wingert, PhD Dated September 6, 1996

Dear Dale,

I have reviewed Dr. Wingerts letter and find that it satisfies NRC requirements for FFD reports I.E. the use of **NEGATIVE** or **POSITIVE** rather than numeric levels in reporting drug test results.

The memo to certifying scientist indicate that internal laboratory procedures are being taken to eliminate erroneous lab reports. Previous conversations with Dr. Wingert indicate that interim steps have been taken to ensure accurate reporting.

As we discussed earlier a probation period during which time no action is taken until final lab reports are received and/or a lab challenge with blind samples appears to be a prudent course.

Sincerely,

Peter C. Gay, M.D., M.R.O.
Medical Review Officer - New York Power Authority